Regulatory mechanisms of surfactant secretion  by Mason, Robert J. & Voelker, Dennis R.
Review
Regulatory mechanisms of surfactant secretion
Robert J. Mason a;b;*, Dennis R. Voelker a;b;c
a Department of Medicine, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
b Department of Medicine, University of Colorado, Denver, CO, USA
c Department of Biochemistry, University of Colorado, Denver, CO, USA
Received 27 March 1998; received in revised form 15 May 1998; accepted 15 May 1998
Abstract
Surfactant secretion is a critical regulated process in the metabolism of pulmonary surfactant. Presumably, because this
process is vital to the survival of the organism, there are several independent pathways for stimulating secretion which work
through different cell surface receptors and signaling mechanisms. In addition, there is apparent homeostatic regulation in
that two components of surfactant, namely SP-A and dipalmitoylphosphatidylcholine, can inhibit secretion. Although
secretion of surfactant has been studied for over two decades, there remains some important issues to be resolved. In vivo
secretion can be stimulated by hyperventilation or even a single large breath. However, we do not know the biochemical
mechanism for this physiologically important form of stimulation. In vitro, we know many of the proximal events in
signaling, but we do not know how the lamellar bodies move within a cell or the docking mechanism at the plasma
membrane. Many investigators have demonstrated that SP-A will inhibit secretion in vitro, but the mechanism is not known.
Finally, there is a route of secretion of SP-A independent of lamellar bodies, but we do not know details of this pathway nor
its regulation. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Secretion of pulmonary surfactant is a rate-limit-
ing step in delivery of surfactant to the air^liquid
interface to lower surface tension in the lung. Secre-
tion is a critical regulated event in the dynamic me-
tabolism of surfactant. The secretion and re-utiliza-
tion cycle of surface active material involves a
number of complex regulated processes that include:
(1) synthesis; (2) intracellular transport; (3) sorting
and packaging in the lamellar bodies; (4) movement
of lamellar bodies to the apical plasma membrane of
the type II cell ; (5) exocytosis; (6) absorption to the
air^liquid interface; (7) physical separation of some
of the surfactant components during compression at
the air^liquid interface; (8) uptake of extracellular
surfactant; (9) intracellular processing of recycled
surfactant components from alveolar £uid (which
likely di¡ers from the intracellular processing of
newly synthesized material); and ¢nally (10) secre-
tion of recycled material. This chapter will focus on
the stimuli for secretion, intracellular movement of
the lamellar body to the apical surface of the mem-
brane, and exocytosis, e.g. steps 4 and 5. Readers are
referred to other reviews on secretion of surface ac-
tive material for a di¡erent perspective and coverage
of additional topics, such as regulation of secretion
at the time of the ¢rst breath in the infant [1^4]. This
review is an update of a previously published review
on the secretion of surface active material [5].
2. Assumptions and a proposed model for secretion
Secretion of the phospholipids of surface active
material is solely by alveolar type II cells and this
intracellular surfactant is stored in lamellar bodies,
unique organelles of type II cells. However, secretion
and tra⁄cking of the proteins of surfactant are more
complex. SP-A may be secreted by routes independ-
ent of lamellar bodies in type II cells and is also
synthesized by other cell types. SP-A, SP-B, and
SP-D are produced by both type II cells and non-
ciliated bronchiolar (Clara) cells. This is especially
true for rodent bronchiolar cells. Human small air-
ways contain little intracellular immunostaining for
SP-A or SP-D. SP-D is not processed with the phos-
pholipids of surfactant and is not found in lamellar
bodies nor in tubular myelin. Hence, for this review,
SP-D is not considered to be part of the surfactant
system. For the discussion that follows, we will ad-
dress issues of lamellar body secretion.
The phospholipid components of surfactant are
found within lamellar bodies in type II cells. This
conclusion is based on chemical analysis of isolated
lamellar bodies, their ultrastructural appearance, and
results of pulse chase metabolic labeling studies. The
phospholipid bilayers within lamellar bodies have
been deemed to be free of protein that spans the
bilayer on the basis of freeze fracture analysis [6].
Within lamellar bodies, there is an electron dense
rim of granular material that is thought to contain
protein. Isolated lamellar bodies have been reported
to contain SP-A, SP-B, SP-C, and certain lysosomal
enzymes [7,8]. However, Power et al. isolated lamel-
lar bodies and a vesicular fraction from rat lung and
found SP-A in the vesicular fraction but not in la-
mellar bodies [9]. Oosterlaken-Dijksterhuis et al. an-
alyzed isolated rat lamellar bodies for their content
of the surfactant proteins [10]. SP-B and SP-C were
highly concentrated in lamellar bodies. SP-B and SP-
C constituted 28% and 22% of total lamellar body
protein, whereas SP-A accounted for only 1% of la-
mellar body protein. Froh et al. also documented a
low amount of SP-A in lamellar bodies and demon-
strated that exogenous SP-A was necessary for struc-
tural transformation to tubular myelin and rapid sur-
face ¢lm formation [11]. Similar analysis of puri¢ed
extracellular surfactant indicated a much di¡erent
relative abundance of the surfactant proteins. SP-A
accounts for 50%, SP-B for 8%, and SP-C for 4% of
the protein in puri¢ed surfactant [10]. The molar
stoichiometry would make SP-C and SP-B the most
abundant surfactant proteins in lamellar bodies. One
interpretation of these data is that SP-A is derived in
part from sources other than lamellar bodies, within
type II cells or Clara cell granules. These observa-
tions are compatible with the suggestion that SP-A
can be secreted by type II cells independent of lamel-
lar body secretion [12^14]. An alternative interpreta-
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tion of the compositional analysis is that the turn-
over of SP-A in extracellular surfactant is much
slower than that of SP-B and SP-C. Our data with
type II cells in vitro indicate that the SP-A found in
lamellar bodies is derived in large part from extra-
cellular pools (K. Osani et al., Tra⁄cking of newly
synthesized surfactant protein A in isolated not al-
veolar type II cells. Am. G. Respir. Cell Mol. Biol.,
in press). In this review, the pathway and regulation
of SP-A secretion which is independent of lamellar
body secretion will not be discussed in more detail
because there is little known about this pathway.
However, it should be noted that Froh et al. have
estimated that this pathway accounts for most of SP-
A secretion [12].
A proposed model for exocytosis of lamellar
bodies is shown in Fig. 1. This model is designed
to conceptualize sites for physiologic and pharmaco-
logic control of lamellar body secretion. Extracellular
mediators combine with their cognate cell surface
receptors designated R in Fig. 1. The physiologically
dominant in vivo agonist and receptor has not been
established. As will be discussed below, there are
many di¡erent agonists that can stimulate secretion.
However, the model can be conceptualized from
analyses of secretion stimulated by ATP and use
the P2Y2 purinoceptor as a model of a seven mem-
brane spanning G-protein coupled receptor [15,16].
The receptor^ligand complex then associates with
the heterotrimeric G-proteins (guanine nucleotide
binding proteins) to activate phospholipase C which
cleaves phosphatidylinositol bisphosphate to form di-
acylglycerol and IP3. Diacylglycerol will activate pro-
tein kinase C and facilitate the translocation of the
soluble form of protein kinase C to the plasma mem-
brane. IP3 di¡uses to intracellular membranes, pre-
dominantly the endoplasmic reticulum, to release
membrane associated calcium. There is also opening
of calcium channels to allow access of extracellular
calcium. The result is a transient rise in intracellular
calcium. It should be noted that there are also cal-
cium-independent pathways for surfactant secretion
that for simplicity are not included in this model, and
these include the cyclic AMP-dependent pathway
Fig. 1. Proposed general mechanism for exocytosis. As stated in the text, the identity of the dominant receptor R in vivo is not
known. The membrane-associated events are well de¢ned in other secretory cell types and in preliminary studies in type II cells. An
agonist combines with the receptor to activate phospholipase C (PLC) via heterotrimeric G-proteins and subsequently protein kinase
C (PK-C). Other intracellular signals, such as Ca2 and cyclic AMP are generated, but are not shown in this diagram. The major
gaps in our knowledge are the subsequent steps. The unknown e¡ectors are presumably cytosolic protein kinases and phosphatases
with subsequent protein phosphorylations and dephosphorylations. Presumably these signals activate contractile proteins to move la-
mellar bodies up to the apical surface and clear the subcortical cytoskeletal network to allow docking with the plasma membrane. La-
mellar bodies then fuse with the apical plasma membrane, an e¡ect which is postulated to be regulated by low molecular weight
monomeric G-proteins such as Rab3A [25,26]. Exocytosis occurs and the lamellar body transforms into tubular myelin before adsorp-
tion to the air^liquid interface. The transformation of lamellar phospholipid into tubular myelin requires SP-B and SP-A.
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[17,18]. The speci¢c substrates for protein kinases
that participate in exocytosis are not known. Ed-
wards et al. and Takahashi and Voelker independ-
ently sought to determine if the MAP (mitogen acti-
vated protein kinase) pathways were involved in
inhibition of secretion mediated by SP-A in vitro
([19] and unpublished observations). Both groups
demonstrated the existence of these kinase pathways
in type II cells and activation by secretagogues.
However, they were unable to demonstrate any rela-
tionship to the inhibition of secretion by SP-A. MAP
kinase was activated by TPA, ATP, and ionomycin,
and this activation was not inhibited by addition of
SP-A. Intracellular e¡ectors presumably calcium, cy-
clic AMP, and phosphorylated proteins di¡use to
activate the lamellar body translocation process.
Although the proximal membrane events for intra-
cellular signalling are established, the more distal
events leading to translocation of lamellar bodies
are not known. A series of coordinated events are
needed to move the lamellar bodies intracellularly.
Lamellar bodies move vectorially to the apical plas-
ma membrane, fuse with the plasma membrane and
are ultimately secreted by exocytosis. The intracellu-
lar movement of lamellar bodies presumably involves
actin [20] and microtubules for the dynamic move-
ment, intermediate ¢laments as the guides [21], and
speci¢c attachment proteins. There needs to be teth-
ering of the contractile proteins to the plasma mem-
brane and to the cytoplasmic surface of the lamellar
body. Annexins, calcium-dependent phospholipid
binding proteins, are likely to be important for the
terminal events in exocytosis and could dock the la-
mellar bodies at the plasma membrane prior to mem-
brane fusion and secretion [22,23]. In order to trans-
port the lamellar body to the apical membrane, the
subapical or cortical cytoskeletal network of actin
¢laments must be depolymerized [24]. Once the la-
mellar body has arrived at the apical membrane, it
must fuse with the plasma membrane before exocy-
tosis. The fusion is thought to involve low molecular
weight monomeric GTP binding proteins of the Rab
family, such as Rab3A [25,26].
3. Regulation of secretion in the intact lung
In order to determine physiologic regulation of
secretion and pharmacologic stimulation of surfac-
tant secretion in patients with respiratory insu⁄-
ciency, we need to understand secretion in the intact
lung. However, control of secretion in the intact lung
remains largely unde¢ned. For studies of secretion,
most investigators have used type II cells in primary
culture, which has limitations for extrapolation to
events in vivo. Secretion in vivo may involve para-
crine and physical forces that are not readily studied
with isolated type II cells.
There are two di¡erent means of stimulating secre-
tion in the intact lung. One is by hyperventilation,
for which agonists (or antagonists) have not been
de¢ned, and the other is by agonists that directly
stimulate type II cells. The calculated rate of secre-
tion of surface active material in vivo is about 10%
of the stored intracellular pool per hour [27,28].
However, the measurements have only quantitated
the turnover of the phospholipid components of sur-
factant. If there is a lamellar body-independent path-
way for secretion of SP-A, such a pathway is prob-
ably also under pharmacologic control and may have
a di¡erent turnover rate. Nicholas and colleagues
stimulated secretion in rats through hyperventilation
caused by swimming or by breathing a gas mixture
of 10% oxygen, 5% carbon dioxide, and 85% nitro-
gen [29^32]. With swimming rats, secretion appears
to be maximally stimulated within a few minutes,
and this stimulation is not inhibited by propranolol,
atropine, cyproheptadine, or indomethacin. These
studies were performed before the identi¢cation of
the purinergic receptor (P2Y2). It is possible that
ATP could be the e¡ector molecule, and inhibition
of the purinergic receptor could block this e¡ect. The
rate of secretion within the ¢rst 10 minutes was cal-
culated to increase by 14-fold over the basal rate. In
the isolated perfused lung, basal secretion can also be
increased by hyperventilation. Several groups have
documented that large in£ations can increase the
amount of phospholipid recovered in lavage [30,33^
36]. Interestingly, a single deep breath also causes
secretion [37]. Pharmacologic attempts to block in-
creased secretion due to hyperventilation have not
been uniformly successful [34,38]. A likely mecha-
nism for the increased secretion due to large tidal
volumes is physical stretch which generates a transi-
ent increase in cytosolic calcium [39]. Alternative
mechanisms include release of mediators such as
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arachidonate metabolites from other lung cells which
in turn stimulate secretion, a reduction in intracellu-
lar pCO2 which produces intracellular alkalosis, and
membrane depolarization due to an opening of ion
channels by stretch. Membrane depolarization pro-
duced by high extracellular potassium moderately
stimulates secretion [40]. The possibility of intracel-
lular alkalosis as a potential mechanism was inves-
tigated by Chander in the isolated perfused lung [41].
In addition, Gerboth et al. demonstrated that intra-
cellular alkalinization increases intracellular calcium
levels in type II cells [42]. Hence, hyperventilation
could stimulate secretion by a calcium-dependent
process.
An important clinical issue is whether exogenous
surfactant used for replacement therapy alters the
secretory rate in vivo. Exogenous surfactant is being
used in the treatment of respiratory distress syn-
drome of the newborn and has been used successfully
in the treatment of adult respiratory distress syn-
drome. Exogenous surfactant could a¡ect endoge-
nous synthesis or secretion. However, data available
to date do not indicate a major decrease in the
secretory rate nor a feedback inhibition of phospho-
lipid or protein components of surface active ma-
terial [28,43^45]. In this regard, the in vivo data are
di¡erent from the in vitro data where both SP-A and
dipalmitoylphosphatidylcholine have been shown to
inhibit secretion.
Pharmacologic agonists can also be administered
to the intact lung to stimulate surfactant secretion. A
variety of agonists stimulate secretion in the isolated
perfused lung, and these include isoproterenol, terbu-
taline, 8-bromoadenosine 3P,5P-cyclic monophos-
phate, TPA and ATP [41,46]. However, the magni-
tude of secretion in the isolated perfused lung is only
about 2% per hour which is low in comparison to
turnover data in the intact animal. Maximal secre-
tion is likely to require both physical forces and me-
diators as occurs with exercise. Since the e¡ects of
agonists are modest compared to hyperventilation, it
appears that regulation in vivo may be controlled
more by physical stretch than by circulating or para-
crine mediators.
The role of inhibitors of secretion can be studied in
vivo and in the isolated perfused lung. As shown in
Fig. 1, there must be some movement of lamellar
bodies within the cytoplasm to the apical membrane,
and such movement would likely involve contractile
proteins, e.g. tubulin and actin. Studies in the intact
lung with normal cell shape and cytoarchitecture
show that both inhibitors of microtubule assembly
(colchicine and vinblastine) and actin polymerization
(cytochalasin D) inhibit secretion [20,21]. However,
the results of these inhibitors in isolated type II cells
are inconsistent [47^49]. The major di¡erences be-
tween the studies with the intact lung and with iso-
lated type II cells are that in vitro the cells are £at-
tened, cell polarity is altered, and the cytoskeleton is
more disorganized. Thus, the studies with the intact
lung are probably more relevant.
4. Regulation of secretion in type II cells in vitro
The development of methods to purify alveolar
type II cells has provided essential tools for analyzing
factors that stimulate surfactant secretion. This sys-
tem a¡ords the opportunity of investigating the role
of speci¢c second messengers in the signal transduc-
tion cascade which cannot be readily studied in the
intact lung because of cellular heterogeneity. How-
ever, the magnitude of secretion in vitro is less than
in vivo. As stated above, basal secretion with normal
respiratory movement is about 10% per hour in vivo.
Basal secretion in vitro in the absence of exogenous
agonists and physical stretch is about 1% per hour.
In the presence of maximal stimulation by agonists in
vitro, but in the absence of stretch, the secretory rate
can reach about 8% per hour. Studies of secretion
with isolated type II cells have shown that there are
multiple stimulatory agonists (TPA, diacylglycerol,
ATP, L-adrenergic agonists, calcium ionophores,
arachidonate metabolites, etc.) as well as inhibitors
(SP-A, dipalmitoylphosphatidylcholine, lectins). Im-
plications of the numerous potential agonists and
antagonists include that control of secretion may be
tightly regulated in the intact lung, that numerous
backup systems are available should one ever fail,
and that secretion may be very di⁄cult to stimulate
or inhibit by a single agonist or antagonist in vivo.
Among the most challenging studies on secretion
in vitro are those on the role of stretch. Although
many investigators considered stretch to be impor-
tant in vivo, Wirtz and Dobbs were the ¢rst to docu-
ment the role of stretch on secretion in vitro [39].
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Type II cells were cultured on elastic silicone mem-
branes coated with ¢bronectin. A single stretch was
applied by hydrostatic pressure and secretion was
measured over a 1 h incubation. Because of technical
di⁄culties, rhythmic stretch was not performed. The
magnitude of secretion was similar to that obtained
with a combination of agonists (ATP, TPA, and ter-
butaline). Stretch was associated with a transient in-
crease in cytosolic calcium, but no change in cyclic
AMP. The stimulation of secretion by stretch was
inhibited by SP-A, but not by cyclooxygenase or lip-
oxygenase inhibitors.
A variety of agonists stimulate secretion in vitro,
as diagrammed in Fig. 2. In general, the e¡ect of
di¡erent types of agonists are additive in the presence
of maximal concentrations [50,51]. This implies that
there are several independent enzymatic cascades
that ultimately lead to secretion. Agonists can be
grouped into those that produce a relatively large
amount of secretion (4-fold over basal secretion)
e.g. TPA and ATP, and those agonists which pro-
duced a lower level of secretion (2-fold over base-
line), e.g. L-adrenergic agonists, cholera toxin, and
calcium ionophores. The implication is that agonists
which utilize protein kinase C (ATP and TPA) are
more e¡ective than those that work through other
protein kinases. In rat type II cells, there is about
6-fold more protein kinase C activity than cyclic
AMP-dependent protein kinase [51]. When type II
cells are damaged, the L-adrenergic response is lost
before the TPA response.
Tetradecanoyl phorbol acetate (TPA) was the ¢rst
agonist reported to stimulate surfactant secretion in
vitro [48]. TPA was especially useful for de¢ning
what was secreted, the time course and magnitude
of secretion in vitro, and the energy dependence of
secretion [52]. TPA activates protein kinase C di-
rectly and does not increase cyclic AMP or cytosolic
calcium [17,53]. A limitation of studies with TPA is
that the physiologic extracellular agonist for activa-
tion of protein kinase C in vivo has not been deter-
mined. However, TPA will continue to be useful for
de¢ning the regulatory role and protein substrates
for phosphorylation by protein kinase C.
A variety of L-adrenergic agonists can also stimu-
late secretion in vitro [46,49,54]. The order of po-
Fig. 2. Regulation of surfactant secretion in vitro. In this diagram, three groups of agonists that result in activation of three di¡erent
families of protein kinase are shown. Secretion can be stimulated by at least three di¡erent pathways and several di¡erent receptors
may be involved in signaling through the protein kinase C pathway. In addition, the interaction of second messengers is more com-
plex than indicated. For example, agents which increase cyclic AMP can also transiently increase cytosolic calcium. The inhibitors of
secretion are depicted to act from the apical surface and the agonists that stimulate secretion are diagrammed to act from the basolat-
eral surface. The mechanisms whereby SP-A and dipalmitoylphosphatidylcholine inhibit secretion is not known. However, for SP-A,
the events appear to be distal in that the generation of intracellular mediators, such as cytosolic calcium and cyclic AMP, are not af-
fected.
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tency is isoproterenols epinephrinesnorepinephrine
which is characteristic of the L2-subtype receptor.
L-Receptors are regulated on type II cells, and ex-
pression can be stimulated by dexamethasone [55,56].
Addition of L-adrenergic agonists produces a prompt
rise in intracellular cyclic AMP [46,49,53]. In addi-
tion, forskolin, cholera toxin, and 8-bromoadenosine
3P,5P-cyclic monophosphate which bypass the L-re-
ceptor also stimulate secretion. The next step in
this pathway is activation of a cyclic AMP-depend-
ent protein kinase.
Purinergic compounds also stimulate secretion
[57^60]. The rank order of potency is ATPs
ADPs adenosine = AMP which is characteristic of
a P2Y2 purinergic receptor. The most potent agonist,
ATP, binds this P2Y2 purinergic receptor which is
coupled to a heterotrimeric G-protein that upon
binding GTP activates phospholipase C to form
IP3 and diacylglycerol [18,60^62]. A P2Y2 purinergic
receptor has been cloned from a rat type II cell
cDNA library [15]. Because an inhibitor of calcium
mobilization prevented the rise of intracellular calci-
um but failed to block secretion, the increase in in-
tracellular calcium is not thought to be absolutely
required for secretion due to ATP [18]. ATP also
increases cyclic AMP in type II cells [60]. In addition
to the P2 receptor there is a A2 subtype of the P1
purinergic receptor which is activated by AMP and
adenosine [63,64]. The physiologic role of ATP, the
dominant purinergic agonist, on secretion in vivo is
unknown. The e¡ect of ATP in vitro is maximal at
10 WM, intracellular concentration is 4^5 mM, and
the calculated concentration in alveolar £uid is 1 mM
[65]. This calculation is based on the amount of ATP
recovered in lavage and an assumption of 0.1 ml of
alveolar £uid in the adult rat lung. Hence, if the
purinergic receptor is located on the apical surface
of the type II cell, it should be maximally stimulated
in vivo by the ATP in alveolar £uid. However, if the
purinergic receptor is only on the basolateral side,
the receptor may not be maximally stimulated at
rest since interstitial £uid should have a lower con-
centration of ATP. One of the attractions to the
importance of the purinergic receptor is that the in-
tracellular concentration of ATP is much higher than
that required for maximal stimulation, and ATP, a
relatively small molecule, could theoretically be re-
leased by stretch. The released ATP would activate
surface receptors and stimulate secretion. Hence, a
local release of ATP could be part of the signal gen-
eration for the e¡ect of stretch. Although this is pure
speculation, it could also provide a catabolic and
regulatory role for apical membrane alkaline phos-
phatase.
Calcium ionophores, A23187 or ionomycin, in-
crease cytosolic calcium primarily by an increased
uptake of extracellular calcium [17,66]. The stimula-
tion of secretion is thought to be via calcium-depend-
ent protein kinases. Agents other than ionophores
that are associated with an increase in cytosolic cal-
cium are stretch, ATP, terbutaline, forskolin, and
8-bromo-cAMP [17,39]. However, as stated above, a
rise in cytosolic calcium may, in some circumstances,
be independent of the e¡ect on secretion. In addition,
lowering intracellular calcium with excess quin 2 has
not provided consistent results. Sano et al. chelated
cytosolic calcium with excess quin 2 and lowered
intracellular calcium from 143 to 31 nM in the ab-
sence of extracellular calcium [17]. Lowering cyto-
solic calcium and preventing a rise in cytosolic cal-
cium only modestly inhibited the secretory response
to terbutaline and 3-isobutyl-1-methylxanthine or
TPA. Independently, Pian et al. performed similar
experiments and inhibited all forms of stimulated
secretion when intracellular calcium was maintained
below 65 nM [66].
Lipid mediators, i.e. arachidonate, PGE2, and
LTE4 have been reported to stimulate secretion of
phosphatidylcholine by isolated type II cells [67,68].
However, the e¡ect of LTE4 is not reproducible and
the modest stimulatory e¡ects can be duplicated by
other unsaturated fatty acids [69]. In addition, cyclo-
oxygenase inhibitors do not block the e¡ect of arach-
idonate. Type II cells produce large amounts of
PGE2 so in concept PGE2 could be an autocrine
stimulant of secretion [70]. Additional agents that
stimulate secretion have been reported, and these in-
clude vasopressin [71], endothelin [72], and serum
lipoproteins [73,74].
There are several classes of molecules that act as
inhibitors of surfactant secretion in vitro. The ¢rst
are de¢ned components of surfactant that could
serve as autocrine physiologic regulators. A second
group are the lectins concanavalin A and wheat germ
agglutinin which can be used as pharmacologic in-
hibitors [75]. A ¢nal group are metabolic inhibitors
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that have been used to demonstrate the energy de-
pendence of secretion and the importance of speci¢c
contractile proteins.
There is biologic plausibility for some type of feed-
back inhibition of secretion by surfactant itself or
components of surfactant. Surfactant remains close
to the apical surface of type II cells, and there is
physical separation of components of surfactant at
the air^liquid interface. When surface area is reduced
and low surface tension is produced, high ¢lm pres-
sure is achieved and components of surfactant are
squeezed from the monolayer. Hildebran et al. calcu-
lated that the ¢nal surface ¢lm of surfactant when it
was compressed to a low surface tension was com-
posed of at least 90% dipalmitoylphosphatidylcholine
[76]. The implication is that the apoproteins, espe-
cially SP-A, and the unsaturated phospholipids are
physically separated from dipalmitoylphosphatidyl-
choline in surface ¢lm by the surface area compres-
sion during normal ventilation. However, nearly
100% of the SP-A in alveolar £uid is presumably
bound to phospholipid.
Dobbs et al. and Rice et al. independently discov-
ered that delipidated puri¢ed SP-A inhibited secre-
tion in vitro [77,78]. SP-A inhibits all forms of ago-
nist induced secretion and is therefore thought to act
distal to the generation of second messengers. For
example, SP-A inhibits secretion stimulated by
stretch, but does not block the transient increase in
cytosolic calcium [39]. There is a very strong corre-
lation between binding of SP-A to type II cells and
inhibition of secretion by SP-A (see Table 1). Max-
Table 1
E¡ect of structural mutations of rat SP-A upon receptor binding and inhibition of surfactant lipid secretion from alveolar type II
cells
SP-A variant Type II cell receptor bindinga Inhibition of secretionb
Wild-type
Rat SP-A Strong Speci¢c
Recombinant rat SP-A [96] Moderate Speci¢ca
Oligosaccharide mutations [96]
N1T Moderate Speci¢c
N1T, N187S Moderate Speci¢c
N187S Moderate Speci¢c
Covalent crosslinking mutations [97]
C6S Weak Very weak, speci¢c
Collagen region deletion [97]
vG8-P80 Absent Non-speci¢c
CRD mutations [98]
E195Q, R197D Absent Very weak, non-speci¢c
R197A Moderate Speci¢c
R197H Weak Speci¢c
R197K Weak Speci¢c
R197D Very weak Weak, speci¢c
R197N Very weak Non-speci¢c
Ca2 ligating mutations [99]
E195A Absent Very weak, speci¢c
E202A Absent Weak, speci¢c
N214A Absent Weak, speci¢c
D215A Absent Very weak, speci¢c
aThe recombinant rat SP-A in these studies was produced in Sf9 or T.ni cells using baculovirus vectors. All recombinant proteins in
this table have reduced hydroxyproline content in the collagen domain of the molecule. The wild-type recombinant protein has re-
duced activity relative to the native rat protein puri¢ed from lung lavage. In general, the recombinant SP-A has an IC50 for competi-
tion for receptor binding that is 2^5-fold higher than that for native rat SP-A and this di¡erence is the basis for the strong and mod-
erate designations. The recombinant protein has an IC50 for inhibition of secretion that is 2^3-fold higher than that for rat SP-A.
bSurfactant lipid secretion can be inhibited by SP-A and a variety of lectins including concanavalin A. The monosaccharide, K-methyl-
mannoside, reverses concanavlin A inhibition of secretion, but not SP-A-mediated inhibition. The reversibility of inhibition by K-meth-
ylmannoside is used to discriminate between a non-speci¢c lectin e¡ect and a speci¢c SP-A-mediated e¡ect [79].
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imal inhibition of secretion and saturation of high
a⁄nity binding of SP-A occurs at a concentration
of 1^5 Wg/ml [79^82]. Chemical modi¢cations of
SP-A that block the inhibition of secretion also block
the ability of SP-A to bind to type II cells, and these
include heat denaturation, alkylation, reduction, re-
ductive methylation, and treatment with cyclohex-
anedione, a reagent used to reversibly alter arginine
residues [78^80,82]. Removal of the oligosaccharide
component of SP-A with endoglycosidase F has no
e¡ect on the biologic activity [80]. Predictably, sev-
eral monoclonal antibodies that block the inhibition
of secretion also block binding of SP-A to type II
cells [80]. One monoclonal has been identi¢ed that
fails to block SP-A-mediated inhibition of secretion
and only partially block receptor binding. A C-ter-
minal peptide of SP-A beginning at Val117 or Gly118
was found not to a¡ect secretion [78]. However, oth-
er evidence suggests that the oligomeric structure of
SP-A is required for binding and for inhibition of
secretion. Thus, failure of a peptide to inhibit secre-
tion may in itself be insu⁄cient evidence to conclude
that the peptide does not contain the cell recognition
site. The biologic e¡ect of SP-A on secretion is
largely attributable to the carbohydrate recognition
domain (CRD) of SP-A [79,83]. Mannose and K-
methylmannoside do not prevent receptor binding
and inhibition of secretion by SP-A, suggesting that
the CRD recognizes complex oligosaccharides per-
haps in combination with peptide determinants. Con-
canavalin A does not block SP-A receptor binding
indicating that this lectin can inhibit secretion via
saccharide ligands that are di¡erent from those rec-
ognized by SP-A. The role of major structural deter-
minants in SP-A upon type II cell receptor binding
and the inhibition of secretion are outlined in Tables
1 and 2. The structural variants of the protein were
created by site directed mutagenesis. The results
shown in Table 1 demonstrate that the oligosacchar-
ides of SP-A do not play an important role in either
receptor binding or the regulation of secretion. Do-
mains of SP-A that play important roles in covalent
(Cys6) or non-covalent (collagen region) oligomeriza-
tion are not required for carbohydrate binding, but
are necessary for high a⁄nity receptor binding and
e¡ective inhibition of surfactant lipid secretion. A
double mutation within the CRD (E195Q and
R197D) eliminates receptor binding and speci¢c in-
hibition of secretion. However, individual mutations
to position 197 give a range of activities. The R197A
mutation is silent, indicating that a positive charge at
this position is not required for activity. The 197H
and 197K mutations cause a signi¢cant decrease in
receptor binding, but still give e¡ective inhibition of
secretion. Introduction of negative charge with the
R197D mutation signi¢cantly reduced both receptor
binding and inhibition of secretion. The R197N sub-
stitution gave the weakest receptor binding and non-
Table 2
Chimeric protein binding to type II cell receptors and inhibition of secretion
SP-A variant Type II cell receptor bindinga Inhibition of secretionb
SP-A:MBP-A chimeras [84]
SP-A(1^218):MBP-A(210^221) Moderate Speci¢c
SP-A(1^203):MBP-A(195^221) Moderate Speci¢c
SP-A(1^194):MBP-A(185^221) Moderate Speci¢c
MBP-A Absent Absent
SP-A:SP-D chimeras [85]
SP-A(1^194):SP-D(321^355) Absent Absent
SP-A(1^173):SP-D(300^355) Absent Absent
SP-A(1^134):SP-D(261^355 Absent Absent
SP-D Absent Absent
aThe chimeric rat SP-A molecules used in these studies were produced in Sf9 or T.ni cells using baculovirus vectors. All recombinant
proteins in this table have reduced hydroxyproline content in the collagen domain of the molecule. The wild-type recombinant protein
has reduced activity relative to the native rat protein puri¢ed from lung lavage.
bSurfactant lipid secretion can be inhibited by SP-A and a variety of lectins including concanavalin A. The monosaccharide, K-methyl-
mannoside, reverses concanavlin A inhibition of secretion, but not SP-A-mediated inhibition. The reversibility of inhibition by K-meth-
ylmannoside is used to discriminate between a non-speci¢c lectin e¡ect and a speci¢c SP-A-mediated e¡ect [79].
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speci¢c inhibition of secretion. Thus, the substitu-
tions of position 197 that preserve activity are either
of minimal side chain length and uncharged or have
some positive character. Mutations within the CRD
that eliminate putative Ca2 binding residues at po-
sitions 195, 202, 214 or 215 completely eliminate
receptor binding and almost all inhibition of secre-
tion.
Another approach to examining the function of
elements of the CRD is to create chimeras with the
closely related proteins MBP-A and SP-D (see Table
2). Interestingly, chimeras of SP-A and mannose
binding protein A (MBP-A) that substituted portions
of the CRD of SP-A with portions of MBP-A main-
tained the ability to inhibit secretion and bind to
type II cells [84] (see Table 2). The result with
SP-A/MBP-A chimeras was surprising. It was antici-
pated that substitution of SP-A with portions of the
other collectins such as MBP-A or SP-D would ab-
rogate the ability of the chimeras to retain the SP-A
functions. Substitution of portions of the CRD of
SP-A with comparable portions of SP-D did result
in a protein that did not bind to type II cells or
inhibit secretion [85]. Additional studies are required
to de¢ne the epitope on SP-A for binding to type II
cells and these future studies would be greatly facili-
tated by determination of the crystal structure of
SP-A.
The e¡ect of puri¢ed, delipidated SP-A on secre-
tion is at least partially inhibited in the presence of
phospholipid. Dobbs et al. found inhibition of secre-
tion by puri¢ed surfactant with an IC50 at a concen-
tration of 8 Wg of protein per ml. Addition of phos-
pholipid vesicles to SP-A preparations attenuated the
protein’s inhibitory e¡ect upon secretion [78]. Since
SP-A binds phospholipid avidly in the presence of
calcium, there is likely to be very little free SP-A in
alveolar £uid. The SP-A present in alveolar £uid is
almost entirely lipid associated. Secretion in vitro is
inhibited by 0.1 Wg/ml of puri¢ed SP-A in the ab-
sence of phospholipid [80] and by about 160 Wg/ml
of isolated whole surfactant [77]. The calculated con-
centration of total SP-A in alveolar £uid ranges from
300 to 1800 Wg/ml [83].
Although highly speci¢c calcium-dependent bind-
ing of SP-A and evidence of internalization of SP-A
has been demonstrated [81,82,86], the cell surface
receptor on type II cells has not been unambiguously
identi¢ed. Type II cells have a single class of high
a⁄nity receptors for SP-A. There are several candi-
date receptors reported, but additional studies are
required to identify the SP-A receptor which is re-
sponsible for inhibition of secretion by SP-A [87^90].
This is an area of research that is progressing rapidly
and should be resolved soon. Assuming the mole-
cular mass of SP-A to be 650 kDa, and the maximal
amount of SP-A bound is 360 ng/106 cells, this
calculates to be 3.5U105 oligomers of SP-A per cell
[81]. SP-A binding is saturable with an apparent
dissociation constant (Kd) of 1 Wg/ml [81]. Both ki-
netic and morphologic evidence shows time and
temperature-dependent internalization. However,
the endosomal compartment which is the initial lo-
cation of internalized SP-A has not been rigorously
de¢ned. The internalized SP-A is not degraded in
20 h [81].
Suwabe et al. demonstrated that saturated phos-
phatidylcholines below their phase transition temper-
atures, e.g. dipalmitoylphosphatidylcholine at 37‡C,
also inhibit secretion in vitro [91]. The biologic im-
plication of this ¢nding is a hypothesis that type II
cells sense the physical state of extracellular phos-
pholipid by some currently unknown means. The
initial ¢nding was that unilamellar liposomes of di-
palmitoylphosphatidylcholine, but not dioleoylphos-
phatidylcholine inhibit secretion in vitro. A broad
range of naturally occurring and chemically synthe-
sized phosphatidylcholines were evaluated, and those
with transition temperatures above 37‡C were inhib-
itory at 37‡C, whereas those with transition temper-
atures below 37‡C were not. If the temperature of
secretion was increased to 42‡C or lowered to
32‡C, the results were predictable based on the phase
transitions of the phosphatidylcholine liposomes.
The implication is that if liposomes or vesicles of
nearly pure dipalmitoylphosphatidylcholine are
formed in vivo, these could serve as autocrine inhib-
itory regulators of secretion in vivo. As mentioned
above, Hildebran et al. have estimated the chemical
composition of the compressed surfactant monolayer
at times of low surface tension, e.g. high ¢lm pres-
sure, to be composed of nearly pure dipalmitoylphos-
phatidylcholine [76]. Hence, liposomes of nearly pure
dipalmitoylphosphatidylcholine could exist in the al-
veolar subphase in vivo and may constitute an im-
portant form of feedback regulation of surfactant
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secretion in the alveolus. The role of exogenous sur-
factants used in replacement therapy have not been
studied in similar in vitro studies but would be un-
likely to inhibit secretion as liposomes of mixed
phosphatidylcholine species.
5. Other secretory proteins
Alveolar type II cells also secrete a variety of other
proteins that are likely to be independent of lamellar
body secretion. The major one is surfactant protein
D which is a calcium-dependent lectin and part of
the host-defense system. SP-D binds to a variety of
microorganisms including viruses, bacteria, Myco-
bacteria, fungi and Pneumocystis carinii [83]. Readers
are referred to the article by Reid in this series for a
comprehensive review on SP-D. Type II cells also
secrete complement components, lysozyme, plasmi-
nogen activator, basement membrane components,
and hydrogen ions. In addition, type II cells secrete
a variety of mediators, cytokines and growth factors
including arachidonate metabolites, IL-8, IL-6, GM-
CSF, TGF-L and potential autocrine growth factors
(TGF-K and heparin binding EGF). Hence, although
this review focused on surfactant, type II cells are
potentially involved in a variety of in£ammatory
and reparative processes in the lung. The secretion
of GM-CSF may, in addition, play a regulatory role
on surfactant catabolism [92].
6. Problems and future directions
Although a great deal has been learned about ag-
onists that stimulate secretion and the second mes-
sengers that these agonists generate, there is still
much that is not known. We do not know the link-
age between the early signals of protein kinase acti-
vation and the later steps of intracellular movement
of lamellar bodies to the apical surface and exocyto-
sis. Although it appears that the mature processed
forms of the hydrophobic proteins SP-B and SP-C
are contained within lamellar bodies, the intracellular
tra⁄cking of SP-A and its pathway for secretion is
controversial. The pathway and regulation of SP-A
secretion that is independent of lamellar body secre-
tion needs to be de¢ned more precisely. It is clear
that SP-A is synthesized by bronchiolar cells as well
as by type II cells in rodent lungs. Is this SP-A in
bronchiolar cells regulated di¡erently from the SP-A
in type II cells? In human airway submucosal glands
only the SP-A 2 gene is expressed [93]. The role of
SP-A in regulation of surfactant secretion in vivo
also requires further study. SP-A inhibits secretion
in vitro and increases uptake of liposomal lipid.
However, there is little alteration in surfactant ho-
meostasis in mice with homozygous null alleles for
SP-A [94,95]. It is di⁄cult to resolve the in vitro
¢ndings of inhibition of secretion and uptake of lipo-
somal lipid by SP-A with the apparent normal func-
tion of the surfactant system in mice that do not
express this protein. Like many important biologic
systems, there may be redundancy, such that in the
normal state, there are no physiologic abnormalities
and that the de¢ciencies only become manifest under
conditions of stress, such as oxygen toxicity, acute
lung injury, etc. The crystal structure of SP-A needs
to be resolved so that more precise structure/func-
tional point mutations can be constructed to de¢ne
the binding of SP-A to receptors on type II cells and
to account for the ability of SP-A to inhibit secre-
tion. Finally, the cDNA for the high a⁄nity receptor
for SP-A on type II cells needs to be cloned and
characterized in detail.
The regulation of secretion in vivo is also incom-
pletely understood. The relative role of physical sig-
nals, such as stretch and biochemical mediators (such
as ATP and L-adrenergic agonists) remains to be
de¢ned. By extrapolation from studies in vitro, max-
imal secretion in vivo is likely to require multiple
agonists. It is not known if pharmacologic stimuli
can augment the increased secretion due to hyper-
ventilation. If hyperventilation produces maximal se-
cretion, administration of pharmacologic stimulants
to patients who are already hyperventilating may be
ine¡ective. By analogy to other processes in the lung,
the physiologic response is likely to be signi¢cantly
modi¢ed by the local biochemical milieu. The role of
various cytokines and the transepithelial potential
di¡erence and pH gradient that occur in vivo have
not been investigated as modulators of secretion.
More research is needed before we can devise a strat-
egy for stimulating secretion in vivo as part of the
treatment of patients with functional surfactant de¢-
ciencies.
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